Life Technologies Buys Protein Purification Company
BAC’s offerings consist of CaptureSelect affinity ligands, affinity resins and services. The company has agreements with Life Technologies and, for process-scale products, with GE Healthcare. In addition to analytical HPLC columns based on BAC technology, Life Technologies also offers Gibco culture media, POROS resins and SEQ rapid molecular kits for bioprocessing. This acquisition allows Life Technologies to further capitalize on growth in biologics manufacturing.
Carlsbad, CA 1/22/12—Life Technologies has acquired Netherlands-based BAC, a provider of protein purification products, including affinity ligands, for biopharmaceutical research and manufacturing. Financial terms were not announced. “Our acquisition of BAC BV positions Life Technologies as a leading provider of end-to-end solutions that are widely utilized in the bioprocess workflow,” said Tony Hunt, head of BioProduction at Life Technologies. “Combining BAC’s current portfolio and pipeline with our pre-existing portfolio expands Life’s product offering and enables us to compete more fully across the protein purification market.” BAC’s 34 employees will join Life Technologies, including CEO Laurens Sierkstra, PhD, and BAC’s facilities in Naarden and Leiden will remain in operation. The acquisition is expected to be neutral to the Life Technologies’ overall return on invested capital three years after close.
